MedTrace Logo

Renal Cancer Detection With Liquid Biopsy

NCT05060783 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-01-30

No results posted yet for this study

Summary

Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.

Conditions

  • Renal Cancer
  • Oncocytoma

Interventions

DIAGNOSTIC_TEST

GaGnostic

Plasma

DIAGNOSTIC_TEST

GaGnostic

Serum

DIAGNOSTIC_TEST

GaGnostic

Urine

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Elypta

    collaborator INDUSTRY

  • Zealand University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2025-07-01
Completion
2027-07-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05060783 on ClinicalTrials.gov